Opinion|Videos|March 26, 2025
Clinical Insights: Incorporating Zanidatamab and Other HER2-Targeted Agents Into the Real-World Practice in Advanced BTC
Panelists discuss how treatment selection among HER2-targeted agents for biliary tract cancer (BTC) depends on multiple factors including patient characteristics and prior therapies, while also considering the role of traditional chemotherapy regimens such as FOLFOX in specific clinical scenarios.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is your general treatment approach when deciding among the available HER2-targeted agents? For those with HER2-positive tumors, are there situations in which you may still proceed with a 5-FU–containing regimen such as FOLFOX?
- Please comment on any differences and/or similarities in practice regarding HER2-directed therapy selection. Please describe any specific patient and/or disease factors considerations in your treatment approach.
Advertisement
Related to this article
Two optimized CD33-directed CAR T-cell therapies generated complete remissions with incomplete count recovery in heavily pretreated relapsed/refractory AML.
Lung cancer experts discuss the optimal management of CNS disease in EGFR-mutated non–small cell lung cancer.
Data for fixed-duration regimens in CLL suggest benefits over chemoimmunotherapy but still require improvements for high-risk patients.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Iza-bren was approved in China for recurrent or metastatic ESCC following progression on platinum-based chemotherapy and PD-1/PD-L1 inhibition.
A research team from Huntsman Cancer Institute at the University of Utah showed a pathway-targeted therapy that could be an effective melanoma treatment.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Orelabrutinib produced efficacy improvements vs chemoimmunotherapy in previously untreated chronic lymphocytic leukemia.
Advertisement
Advertisement
Trending on OncLive
1
Subcutaneous Pembrolizumab Faces Scrutiny Over Convenience and Cost for Patients With Cancer
2
Orelabrutinib Generates Significant Survival Benefits in Treatment-Naive CLL
3
Experts Unpack Crucial Hematologic Oncology Data From ASCO 2026
4
China’s NMPA Approves Iza-Bren for Pretreated Recurrent/Metastatic ESCC
5